| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
IGC Pharma, Inc. (NYSE: IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease. The new site, Ichor Research, located in Syracuse, New York, is led by Principal Investigator Dr. Karl F. Hafner, M.D.
Dr. Hafner brings years of experience in clinical research and patient care, particularly in the field of neurodegenerative conditions. Ichor Research began enrolling eligible participants for the CALMA trial immediately.
The CALMA Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of IGC-AD1 in reducing agitation symptoms in individuals living with Alzheimer's disease. Agitation is one of the most prevalent and distressing behavioral symptoms in Alzheimer's patients, often accelerating disease progression and increasing caregiver burden.
Posted In: IGC
